Central nervous system Coccidioides immitis infections

Current Treatment Options in Neurology

Volumn 7, Issue 2, 2005, Pages 157-165

  Davis, Larry E ^a   Porter, Beth S ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CISAPRIDE; COMPLEMENT; ERGOT ALKALOID; FLUCONAZOLE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; MEFLOQUINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; QUINIDINE; RAPAMYCIN; RIFAMPICIN; SULFAMETHOXAZOLE; SULFONYLUREA DERIVATIVE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARACHNOIDITIS; BACKACHE; BLADDER DYSFUNCTION; BRAIN ABSCESS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COMPLEMENT FIXATION TEST; CRANIAL NERVE PARALYSIS; DIAGNOSTIC TEST; DIETARY INTAKE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FUNGEMIA; FUNGUS ISOLATION; GRANULOMATOSIS; HEADACHE; HEPATITIS; HUMAN; HYPOKALEMIA; IMMUNOPATHOLOGY; INTESTINE FUNCTION DISORDER; JAUNDICE; LIFESTYLE; LIVER DYSFUNCTION; LUNG INFECTION; MENINX; NAUSEA; NEPHROTOXICITY; NEUROSURGERY; NONHUMAN; PARESTHESIA; PHOTOPHOBIA; QT PROLONGATION; RADICULAR PAIN; RADICULOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; SPINAL CORD DISEASE; TORSADE DES POINTES; TRAVEL; TREATMENT PLANNING; UNITED STATES; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

EID: 14744294586     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0025-z     Document Type: Review

References (38)

1. Stevens DA: Coccidioidomycosis. N Engl J Med 2000, 332:1077-1082.
2. Chiller TM, Galgiani JN, Stevens DA: Coccidioidomycosis. Infect Dis Clin N Am 2003, 17:41-57.
3. Vaz A, Pineda-Roman M, Thomas AR, Carlson RW: Coccidioidomycosis: an update. Hosp Pract 1998, 33: 05-108, 113-115, 120.
4. McGahan JP, Graves DS, Palmer PES, et al.: Classic and contemporary imaging of coccidioidomycosis. AJR 1981, 136:393-404.
5. Powderly WG: Fungal infections in patients with AIDS. Current Treatment Options in Infectious Diseases 2001, 3: 15-522.
6. Bouza E, Dreyer JS, Hewitt WL, Meyer RD: Coccidioidal meningitis: an analysis of thirty-one cases and review of the literature. Medicine 1981, 60:139-172.
7. Vincent T, Galgiani JN, Huppert M, Salkin D: The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis 1993, 16:247-254.
8. Mischel PS, Vinters HV: Coccidioidomycosis of the central nervous system: Neuropathological and vasculopathic manifestations and clinical correlates. Clin Infect Dis 1995, 20:400-405.
9. Saitoh A, Homans J, Kovacs A: Fluoconazole treatment of coccidioidal meningitis in children: two case reports and a review of the literature. Pediatr Infect Dis J 2000, 19:1204-1208.
10. Banuelos AF, Williams PL, Johnson RH, et al.: Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996, 22:240-250.
11. Erley WK, Bellon RJ, Seerer JF, Carmody RF: MR imaging of acute coccidioidal meningitis. AJNR Am J Neuroradiol 1999, 20:509-514.
12. Smith CE, Saito MT, Simons SA: Patterns of 39,500 serologic tests in coccidioidomycosis. JAMA 1956, 160: 46-552.
13. Ragland AS, Arsura E, Ismail Y, Johnson R: Eosinophilic pleocytosis in coccidioidal meningitis: frequency and significance. Am J Med 1993, 95:254-257.
14. Stevens DA: Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002, 49(suppl S1):11-19.
15. McNeil MM, Ampel NM: Opportunistic coccidioidomycosis in patients with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis 1995, 21(suppl 1):S111-113.
16. Labadie EL, Hamilton RH: Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch Intern Med 1986, 146:2013-2018.
17. Galgiani JN, Catanzaro A, Cloud GA, et al.: Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993, 119:28-35.
18. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V: The lipid formulations of amphotericin B. Expert Opin 2003, 4:1277-1287.
19. Dupont B: Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002, 49 (suppl 1): 1-36.
20. Clemons KV, Sobel RA, Williams PL, et al.: Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002, 46: 420-2426.
21. Galgiani JN, Ampel NM, Cantanzaro A, Johnson RH, Stevens DA, Williams PL: Practice guidelines for treatment of coccidioidomycosis. Clin Infect Dis 2000, 30:658-661.
22. Terrell CL: Antifungal agents. Part II. The Azoles. Mayo Clin Proc 1999, 74:78-100.
23. Groll AH, Gea-Banacloche JC, Glasmacher A, et al.: Clinical pharmacology of antifungal compounds. Infect Dis N Am 2003, 17:159-191.
24. Tucker RM, Denning DW, Dupont B, Stevens DA: Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990, 112:108-112.
25. Tucker RM, Galgiani JN, Denning DW, et al.: Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 1990, 12(suppl 3):S380-389.
26. Dewsnup DH, Galgiani JN, Graybill R, et al.: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996, 124:305-310.
27. Kelly PC, Sievers MI, Thompson R, Echols C: Coccidioidal meningitis: results of treatment in 22 patients. In Coccidioidiomycosis: Current Clinical and Diagnostic Status. Edited by Ajello L. Miami: Symposia Specialists; 1977:239-251.
28. Perez JA, Johnson RH, Caldwell JW, et al.: Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med 1995, 155: 665-1668.
29. Stevens DA, Shatsky SA: Intrathecal amphotericin in the management of coccidioidal meningitis. Sem Resp Infect 2001, 16:263-269.
30. Keane JR: Cisternal puncture complications. Treatment of coccidioidal meningitis with amphotericin B. Calif Med 1973, 119:10-15.
31. Adler-Moore J, Proffitt RT: Effect of tissue penetration on AmBisome efficacy. Curr Opin Invest Drug 2003, 4: 79-185.
32. Dismukes WE: Introduction to antifungal drugs. Clin Infect Dis 2000, 30:653-657.
33. Romero JH, Rice LB, McQuarrie IG: Hydrocephalus in coccidioidal meningitis: case report and review of the literature. Neurosurgery 2000, 47:773-777.
34. Davis LE, Cook G, Costerton JW: Biofilm on ventriculo-peritoneal shunt tubing as a cause of treatment failure in coccidioidal meningitis. Emerg Infect Dis 2002, 8:376-379.
35. Diamond RD, Bennett JE: A subcutaneous reservoir for intrathecal therapy of fungal meningitis. N Engl J Med 1973, 288:186-188.
36. Albanese A, Hindmarsh, Stanhope R: Management of hyponatraemia in patients with acute cerebral insults. Arch Dis Child 2001, 85:246-251.
37. Jeu LA, Piacenti FJ, Lyakhovetskiy AG, Fung HB: Voriconazole. Clin Ther 2003, 25:1321-1381.
38. Cortez KJ, Walsh TJ, Bennett JE: Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619-1622.